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The FUSE binding proteins FBP1 and FBP3 are potential c-myc
regulators in renal, but not in prostate and bladder cancer
Abstract
BACKGROUND: The three far-upstream element (FUSE) binding proteins (FBP1, FBP2, and FBP3)
belong to an ancient family of single-stranded DNA binding proteins which are required for proper
regulation of the c-myc proto-oncogene. Whereas it is known that c-myc alterations play a completely
different role in various carcinomas of the urogenital tract, the relevance of FBPs is unclear. Methods:
FBP1, FBP3 and c-myc expression was studied in 105 renal cell, 95 prostate and 112 urinary bladder
carcinomas by immunohistochemistry using tissue microarrays. High rates of FBP1 and FBP3
expression were observed in all cancer types. RESULTS: There was a concomitant up-regulation of
FBP1 and FBP3 in renal cell and prostate carcinomas (p<0.001 both). C-myc expression was detectable
in 21% of prostate, 30% of renal and 34% of urothelial carcinomas. Interestingly, strong FBP1 and
FBP3 expression was associated with c-myc up-regulation in clear cell renal cell carcinomas (p<0.001
and 0.05 resp.), but not in bladder or prostate cancer. CONCLUSIONS: The correlation between
FBP1/FBP3, c-myc and high proliferation rate in renal cell carcinoma provides strong in vivo support
for the suggested role of FBP1 and FBP3 as activators of c-myc. The frequent up-regulation of FBP1
and FBP3 in urothelial and prostate carcinoma suggests that FBPs also have an important function in
gene regulation of these tumors.
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Abstract
Background: The three far-upstream element (FUSE) binding proteins (FBP1, FBP2, and FBP3)
belong to an ancient family of single-stranded DNA binding proteins which are required for proper
regulation of the c-myc proto-oncogene. Whereas it is known that c-myc alterations play a
completely different role in various carcinomas of the urogenital tract, the relevance of FBPs is
unclear.
Methods: FBP1, FBP3 and c-myc expression was studied in 105 renal cell, 95 prostate and 112
urinary bladder carcinomas by immunohistochemistry using tissue microarrays.
Results: High rates of FBP1 and FBP3 expression were observed in all cancer types. There was a
concomitant up-regulation of FBP1 and FBP3 in renal cell and prostate carcinomas (p < 0.001 both).
C-myc expression was detectable in 21% of prostate, 30% of renal and 34% of urothelial carcinomas.
Interestingly, strong FBP1 and FBP3 expression was associated with c-myc up-regulation in clear cell
renal cell carcinomas (p < 0.001 and 0.09 resp.), but not in bladder or prostate cancer.
Conclusion: The correlation between FBP1/FBP3, c-myc and high proliferation rate in renal cell
carcinoma provides strong in vivo support for the suggested role of FBP1 and FBP3 as activators of
c-myc. The frequent up-regulation of FBP1 and FBP3 in urothelial and prostate carcinoma suggests
that FBPs also have an important function in gene regulation of these tumors.
Background
The three far-upstream element (FUSE) binding proteins
(FBP1, FBP2, and FBP3), encoded by different genes, com-
prise an ancient family of single-strand DNA-binding pro-
teins which have different functions in gene regulation.
Though the FBP1, FBP2, and FBP3 genes are located on
different chromosomes in mice as well as in humans, their
primary sequences are highly related [1-3]. The genes
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1p31.1 and 9q34.11, respectively. FBP1 (FBP) is desig-
nated the family progenitor. Besides regulating the tran-
scription of the c-myc proto-oncogene [4-6], the FBP
family has been shown to bind a variety of RNAs, there-
fore, FBPs are likely to be multifunctional.
The far upstream element (FUSE) of the human c-myc
proto-oncogene stimulates expression of c-myc in undif-
ferentiated cells. FBP1, FBP2, and FBP3 are single-strand
DNA-binding proteins that recognize FUSE. They posses
all features of conventional transcription factors. The FBPs
each bind sequence-specifically to only one strand of the
far upstream element (FUSE; originally identified
upstream of the c-myc promoter), and each has potent
activation domains [1]. We recently have shown that FBP
is required for proper regulation of the c-myc proto-onco-
gene [6,7]. In the absence of FBP, which binds to the sin-
gle-stranded FUSE, the remainder of the set fails to sustain
endogenous c-myc expression. A dominant-negative FBP
arrests cellular proliferation and extinguished native c-myc
transcription [4]. Expression of FBP is regulated during
differentiation of several tissues [8]. FBP is present in
undifferentiated, but not differentiated cells of the human
pro-monomyeloleucocytic cell line HL60. Expression of
FBP mRNA declines upon differentiation, suggesting tran-
scriptional regulation of FBP [9]. In addition, ubiquitina-
tion and degradation of FBP, mediated by p38, leads to
down-regulation of c-myc, which is required for differenti-
ation of functional alveolar type II cells [10].
The c-myc proto-oncogene, coding for a basic helix-loop-
helix leucine zipper (bHLHZ) transcription factor, is
involved in the regulation of about 10–15% of all genes –
not only of class II, but also genes of class I and III, making
c-myc a master regulator for central cellular processes such
as proliferation, differentiation, apoptosis, growth and
cell death. It is involved in the tumorigenesis of many
human tumors [11,12] including urogenital carcinomas.
Alterations of the c-myc genomic region are well docu-
mented for prostate cancer [13-15] as well as bladder can-
cer [16]. In contrast, genomic alterations of c-myc are
mostly subordinate for cell renal carcinoma with the
exception of papillary renal cancer [17-19].
Here, we have analyzed the expression of FBP1 (as the
family progenitor and a moderate transcriptional activa-
tor) and FBP3 (as the strongest transcriptional activator of
this family, [20]) as well as c-myc in renal cell carcinomas
(RCC), prostate (PCA) and urothelial cancers of the uri-
nary bladder. We found that FBP1 as well as FBP3 are
more frequently expressed in prostate and bladder cancer
than in renal cancer. In addition, a positive correlation
between levels of FBP1, FBP3 and c-Myc was exclusively
detectable in RCC.
Methods
Patients
Prostate carcinoma
Paraffin blocks from 95 prostatectomy specimens were
retrieved from the archives of the Institute of Pathology,
Charite Campus Mitte, Berlin, Germany. Forty-four cases
were pT2, 50 cases were pT3, one case was pT4. Twenty-
four cases (25%) had a Gleason score (GS) of 2–6, 39
cases (41%) had a GS of 7 and 31 (43%) cases had a GS
of 8–10 (one missing due to anti-androgenic therapy).
Median follow up time concerning PSA values was 43
months (range 3–180 months). Median patient age was
61 years.
Bladder urothelial carcinoma
We enclosed 147 patients with newly diagnosed primary
non-invasive (pTa) papillary bladder cancer who under-
went transurethral surgical resection (TUR) at the Carl-
Thiem Hospital Cottbus, Germany, between 1997 and
2004. Grading according to WHO 1973 and WHO 2004
was done retrospectively (G.K.). Median follow up time
for patients without disease progression was 53 months.
Sixty-three patients (42.6%) suffered a histologically con-
firmed disease recurrence.
Renal cell carcinoma
Tumor tissue of 104 adult patients with RCC undergoing
radical nephrectomy at the Department of Urology of the
University Hospital Charité, Berlin, Germany between July
2003 and January 2006 was analyzed. According to the his-
tological type, these included 83 clear cell, 16 papillary, and
five chromophobe renal cell carcinomas, respectively.
Tumor stage and classification were established according to
the 2002 TNM System and the 2004 WHO Classification.
Tumor pT-status was as follows: 53 pT1 (51%), three pT2
(3%), 45 pT3 (43%) and three pT4 (3%). According to Fuhr-
man, 11 tumors were G1, 73 tumors G2 and 20 tumors G3.
Twenty-one tumors were pM1.
TMAs
Tissue microarrays (TMA) with 109 renal cell carcinomas, 95
prostate and 147 urinary bladder cancers, respectively, have
been constructed as described [21]. Suitable areas for tissue
retrieval were marked on H&E-stained sections, punched out
of the paraffin block (1.5 mm punch diameter for prostate
and bladder cancer, 0.6 mm punch diameter for renal cell
cancer), and inserted into a recipient block using a tissue
arrayer (Beecher Instruments, Woodland, USA). The tissue
array was cut without any sectioning aiding tapes, and sec-
tions (2 μm tick) were mounted on Superfrost slides (Men-
zel-Gläser, Braunschweig, Germany).
Immunohistochemistry
TMA sections were de-paraffinized in xylene and gradually
hydrated. All TMAs were analyzed with the VentanaPage 2 of 11
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Systems, Tucson, AZ) using Ventana reagents for the entire
procedure. For immunostaining, commercially available
antibodies against FBP1 (C-20, sc-11101, Santa Cruz Bio-
technology, Heidelberg, Germany), FBP3 antibodies (E-
15, sc-11104, Santa Cruz Biotechnology, Inc.), Ki-67
(clone MIB1, Dianova, Hamburg, Germany), and c-Myc
(mouse monoclonal, 9E11, Novocastra Laboratories Ltd,
Newcastle upon Tyne, UK) were used and adjusted to the
Ventana Benchmark (Ventana Medical Systems, Tucson,
AZ) system. Titrations and initial reactivity assessment
were performed on TMAs containing multiple tissues of
different histogenetic origin. Sections were treated with
and without a heat-based steamer using various antigen
different retrieval solutions (citrate buffer, EDTA buffer,
cell conditioning solution). Clear nuclear staining was
achieved at a dilution of 1:100 (concentration, 2 μg/mL)
for FBP1 and FBP3 (Figure 1, 2, 3), 1:400 for c-Myc, and
1:1000 for Ki-67, respectively, which was used for all anal-
ysis (Figure 4). Primary antibodies were detected using the
iVIEW DAB detection kit and the signal enhanced with the
amplification kit. Slides were counterstained with hema-
toxylin, dehydrated and mounted.
With this protocol, a nearly exclusively nuclear (FBP1) or
predominantly nuclear (FBP3) staining product was iden-
tified, in line with what was observed before in cell lines
by transmission and confocal fluorescence microscopy
[20,22]. For both, FBP1 and FBP3, only nuclear staining
was assayed. Intensity of staining was scored in a semi-
quantitative approach as score 0 (none to very faint),
score 1 (weak), score 2 (moderate), or score 3 (strong).
For c-Myc, a stringent evaluation protocol with high dilu-
tion of antibody was used, and only a nuclear signal was
interpreted as positive staining (score 0: negative, or score
1: positive). For Ki-67, percentage of positive tumor cells
was recorded for correlation analysis. For statistical evalu-
ation of Ki-67 in RCC, the Ki-67 count was dichotomized
in low (< 1%) versus high rates (> 1%) of expression.
Statistics
Statistical Product and Service Solutions (SPSS) software
15.0 for windows (SPSS Inc., 1989–1999) was used to cal-
culate statistics. Bivariate correlations were calculated
according to Spearman. In crosstabs, Fishers exact test,
Chi square test and Chi square test for trends were
applied. Results were considered statistically significant if
p-values were 0.05.
Results
FBP1 and FBP3 expression in normal tissues
So far, immunohistochemisty for FBP1 and FBP3 in
human tissues has not been reported. Therefore, we first
sought to evaluate immunostaining with the antibodies
used in this study on TMAs containing normal and tumor
samples of different histogenetic origin. For this, a stain-
ing pattern corresponding to what has been reported
before in cell lines by transmission and confocal fluores-
cence microscopy [20,22] was regarded as specific: a
nearly exclusively nuclear staining for FBP1, and an at
least predominantly nuclear staining product in the cases
of FBP3. Indeed, for both transcription factors, immuno-
histochemistry revealed a nuclear signal in normal kid-
ney, prostate and urothelium. For FBP3, a weak
cytoplasmic reactivity was also detectable. Tubular epithe-
lium of the nephron revealed a distinct differential stain-
ing pattern of FBP1 or FBP3: distal tubules showed a
moderate FPB1 expression, whereas proximal tubules
were negative for FBP1 and FBP3. Podocytes and endothe-
lia of the Bowman capsule were FBP1 and FBP3 positive
(Figure 2A). FBP3 expression was found in most epithelia
of proximal and distal tubules (Figure 2E). FBP1 and FBP3
respectively were expressed in normal urothelium of the
urinary bladder.
FBP1 and FBP3 expression in prostate cancer
Expression of FBP1 and FBP3 was detectable in luminal
epithelia of normal glands, prostatic intraepithelial neo-
plasia (PIN; Figure 1B) as well as adenocarcinomas of the
prostate. FBP1 was interpretable in 91 of 95 tissue cores
on the TMA. FBP3 was interpretable in all tissue cores. All
tumors showed at least a weak FBP1 and FBP3 expression.
Twelve tumors revealed a weak expression (10.9%) (Fig-
ure 1C), 50 tumors a moderate expression (45.5%), and
29 a strong expression of FBP1 (26.4%) (Figure 1D). For
FBP3, 18 tumors revealed a weak expression (16.4%) (Fig-
ure 1G), 48 tumors a moderate expression (43.6%), and
29 a strong expression of FBP3 (26.4%)(Figure 1H). For
statistical analysis, weak and moderate FBP expression
was lumped (low) and opposed to strong expression
(high).
A strong positive association was found between the
expression intensities of FBP1 and FBP3, respectively.
Expression of FBP1 or FBP3 was not associated with clin-
ico-pathological variables (Table 1).
FBP1 and FBP3 expression in renal cancer
Staining of FBP1 was evaluable in 104 renal cell carcinomas.
Of these, 19 tumors were FBP1 negative (17.4%) (Figure
2B). 49 tumors revealed a weak expression (45.0%), 31
tumors a moderate expression (28.4%) (Figure 2C), and 5 a
strong expression of FBP1 (4.6%) (Figure 2D). Staining of
FBP3 was analyzable in a total of 105 RCCs, with 12 tumors
being negative for FBP3 (11.0%) (Figure 2F). 47 tumors
revealed a weak expression (43.1%), 37 tumors a moderate
expression (33.9%), and nine a strong expression of FBP3
(8.3%) (Figure 2G&2H). Negative and weak versus moder-
ate and strong FBP immunoreactivity was lumped (low vs.Page 3 of 11
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Expression of FBP1 and FBP3 in normal prostate and prostate cancerFigure 1
Expression of FBP1 and FBP3 in normal prostate and prostate cancer. A) Normal prostatic epithelium with a strong 
nuclear expression of FBP1, basal cells are mostly devoid of FBP1 expression (40×). B) Prostatic intraepithelial neoplasia (PIN) 
also shows a strong nuclear signal for FBP1 (40×). C) Prostate cancer with weak FBP1 expression (20×). D) Prostate cancer 
with strong FBP1 expression (20×). E) Normal prostatic epithelium also reveals a strong nuclear expression of FBP3, basal cells 
are again mostly negative for FBP3 (40×). F) Normal gland (central), surrounded by invasive carcinoma with equal FBP3 expres-
sion (20×). G) Prostate cancer with low FBP3 expression (20×). H) Prostate cancer with high FBP3 expression (20×).
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FBP1 and FBP3 expression in normal kidney and renal cancerigure 2
FBP1 and FBP3 expression in normal kidney and renal cancer. A) Normal renal tissue shows a moderate FPB1 
expression in epithelia of distal tubules, whereas proximal tubules show no immunoreactivity. Podocytes and endothelia of the 
Bowman capsule are also FBP1 positive (20×). B) ccRCC lacking FBP1 expression (20×).C) ccRCC with moderate FBP1 immu-
noreactivity (20×). D) Example of a strong FBP1 expression in a ccRCC, 20×. E) Normal renal tissue with a strong FBP3 
expression in epithelia of proximal and distal tubules (40×). F) FBP3-negative ccRCC (20×). G) FBP3 positive papillary RCC 
(20×). H) ccRCC with strong FPB3 expression (20×).
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FBP1 and FBP3 expression in normal urothelium and cancer of the urinary bladderigure 3
FBP1 and FBP3 expression in normal urothelium and cancer of the urinary bladder. Papillary bladder cancer with 
weak (A), with moderate (B), and with strong (C) expression of FBP1 (all 20×). D) Illustration of the heat sensitivity of the 
FBP1 epitope, which is not detectable in coagulated areas (centrally), whereas the signal is well retained at the periphery 
(arrow). Papillary bladder cancer with weak (E, 20×), moderate (F, 40×; G, 20×)), and with a strong (H, 40×) expression of 
FBP3, respectively.
BMC Cancer 2008, 8:369 http://www.biomedcentral.com/1471-2407/8/369high) for statistical analysis. A strong positive association was
found between the expression intensities of FBP1 and FBP3,
respectively (Table 2). Importantly, there was an association
between high FBP expression levels and the renal tumor sub-
type. High FBP1 expression was more frequent in papillary
RCC (68.8%) than in clear cell RCC (30.1%; p < 0.003). A
similar trend was observed for FBP3 (p = 0.052). In clear cell
RCC, FBP3 expression was associated with tumor stage: high
FBP3 expression was less frequent in pT3/4 stage (25.6%%)
than in pT1/2 stage (52.5%; p = 0.014). There were no other
correlations between the expression of FBP1 or FBP3 and
clinicopathological parameters (Table 2).
FBP1 and FBP3 expression in urothelial cancer of the 
urinary bladder
FBP1 immunohistochemistry was evaluable in 112
urothelial carcinomas. Thirty-seven revealed a weak
expression (33%) (Figure 1A), 56 tumors a moderate
expression (50%) (Figure 1B), and 19 a strong expression
of FBP1 (17%) (Figure 1C). FBP3 was analyzable in 102
bladder cancer cases: 25 tumors revealed a low expression
(25%) (Figure 3E), 57 tumors showed a moderate expres-
sion (57%) (Figure 3F&3G), and 20 a strong expression of
FBP3 (20%)(Figure 3H). In contrast, to PCAs and RCCs,
the co-expression of FBP1 and FBP3 failed statistical sig-
nificance but showed a clear trend with 53 tumors that
had high levels of FBP1 and FBP3 (p = 0.067). Addition-
ally, high FBP1 expression was significantly more frequent
in low grade (71.9%) than in high grade (47.8%) tumors
(p = 0.029)(Table 3).
c-Myc and FBP expression
To determine c-Myc protein expression in relation to FBP
expression levels, we developed a stringent protocol for c-
Myc immunohistochemistry. Using this protocol, there
was no c-Myc staining in non-tumoral tissues (Figure 4A).
Expression of c-Myc in normal kidney and renal cancerFigure 4
Expression of c-Myc in normal kidney and renal cancer. In non-tumor kidney tissue, no positive staining was found for 
c-Myc (A, 40×), and most renal cell carcinomas as were negative (B, 40×). Positive cases revealed staining for c-Myc only in a 
proportion of tumor cells (C, 40×).Page 7 of 11
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BMC Cancer 2008, 8:369 http://www.biomedcentral.com/1471-2407/8/369In contrast, c-Myc was detectable in about one third of all
tumors: 21.3% of prostate carcinomas, 29.9% of renal cell
carcinomas, and 33.9% of urothelial carcinomas were
positive.
In prostate cancer, c-Myc did neither correlate to pT stage,
Gleason score and preoperative PSA levels nor to FBP1/
FBP3 expression or Ki-67 fraction.
In bladder cancer, c-Myc correlated to tumor grading
(WHO 2004: correlation coefficient 0.267, p = 0.003), but
did not correlate to FBP1 or FBP3 expression or Ki-67 frac-
tion.
In renal cell cancer, no correlations of c-Myc with pT stage,
M stage, grading or histology were found. On stratified
analysis, a significant association of c-Myc and FBP1 (p =
0.001) expression (Table 4. Figure 4B–D) was apparent in
clear cell RCC. 62.5% of clear cell RCC with high FBP1
were c-Myc positive. In contrast, c-Myc expression was
only seen in 20.7% of clear cell RCC with low FBP1
expression. Such a trend was also observed for FBP3 (p =
0.09). Additionally, a highly significant association
between high levels of FBP1 and high tumor cell prolifer-
ation rate (Ki-67) (p = 0.001) was noted. This is in sharp
contrast to papillary renal cell carcinomas. In this tumor
subtype, no association between FBP1/FBP3 expression
and c-Myc or Ki-67 fraction was seen (data not shown).
Discussion
The single-stranded binding proteins FBP1 and FBP3 are
involved in the regulation of many cellular processes,
such as gene expression and differentiation of several tis-
sues [4,7,8,10]. With this, FBPs obviously are potential
targets of a malignant cell transformation. The major aim
of this study was to evaluate FBP1 and FBP3 expression in
urogenital tumors and to elucidate the relationship to c-
Myc expression. Our study showed different expression
levels of the single-stranded proteins in renal cancer sub-
types, as well as in bladder and prostate cancer. Further,
we demonstrate a significant correlation between FBP1
and c-myc expression in clear cell renal cancer, whereas
there was no such correlation in renal papillary, prostate
and bladder cancer.
In previous studies, we and others have investigated FBP1
and FBP3 expression in human cell lines by either
immunofluorescence studies or fusion protein experi-
ments in cell culture systems [6,20,22,23]. Here, we have
extended FBP expression analysis to primary non-neo-
plastic and neoplastic human tissues using immunohisto-
chemistry. Remarkably, the subcellular localization
patterns of FBP1 and FBP3 with a nearly exclusive (in case
of FBP1) or at least predominant localization (in case of
FBP3) in the nucleus we observed by means of immuno-
histochemistry were similar to what has been described
before. The overlapping data on subcellular localization
patterns from the previously reported cell culture studies
Table 1: Associations between FBP1 and -3 and clinical parameters in prostate cancer (low, high expression: for definition see text). 
FPB1 FBP3
n low
n (%)
high
n(%)
p-value n low
n (%)
high
n(%)
p-value
pT2 42 29 (69.0) 13
(31.0)
n.s. 44 31
(70.5)
13
(29.5)
n.s.
pT3/4 49 33
(67.3)
16
(32.7)
51 35
(68.6)
16
(31.4)
Gleason score 2–6 23 16
(69.6)
7
(30.4)
n.s. 24 14
(58.3)
10
(41.7)
n.s.
Gleason score 7–10 67 46
(68.7)
21
(31.3)
70 51
(72.9)
19
(27.1)
PSA relapse 48 34
(70.8)
14
(29.2)
n.s. 49 32
(65.3)
17
(34.7)
n.s.
No PSA relapse 43 28
(65.1)
15
(34.9)
46 34
(73.9)
12
(26.1)
FBP1 low 62 62 48
(77.4)
14
(22.6)
0.017
FBP1 high 29 29 15
(51.7)
14
(48.3)
FBP3 low 63 48
(76.2)
15
(23.8)
0.017 66
FBP3 high 28 14
(50.0)
14
(50.0)
29
n.s.: not significantPage 8 of 11
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and FBP3 were report here is a reliable means of studying
these proteins. Furthermore, our observations in primary
human tissues confirm previous data ascribing FBPs
mainly a function as transcription factors.
Since previous studies on FBPs revealed an important role
of these proteins in the regulation of the c-myc oncogene,
we studied c-Myc protein levels. So far, very different
immunohistochemical staining patterns and intensities
are reported for c-Myc. Therefore, we deemed using a
stringent protocol for c-Myc immunohistochemistry
indispensible for reliable c-Myc staining. With this, we
have observed no staining in non-tumoral tissues, and
nuclear staining in roughly one third of all tumors. The
results obtained with our immunohistochemical staining
protocol are highly congruent with these reported find-
ings. Therefore, we regard our c-Myc staining as specific.
With this immunohistochemical procedure, we found dif-
ferent patterns between FBP1, FBP3 and c-myc expression
in the different tumor types. Clear cell RCC was the only
tumor type with a positive correlation of FBP1 and FBP3
expression levels with c-Myc expression. This may recapit-
ulate the view that FBPs are activators of c-myc in renal can-
cer. While c-myc alterations on the genomic level have
been reported in prostate [13-15] and bladder cancer [16],
DNA copy number changes of c-myc have been identified
only in papillary, but not in clear cell RCC [17-19]. It is
tempting to speculate that c-myc expression in bladder,
prostate and papillary renal cancer is rather due to c-myc
copy number alterations, than a consequence of FBP over-
expression, whereas clear cell RCC without c-myc DNA
copy number alterations require FBPs for c-Myc regula-
tion. We have recently shown that an intact chromosomal
architecture of the c-myc regulator region is required for
proper regulation of the c-myc gene by the FBPs [6,7,23].
The strong positive correlation between FBP1 expression
and c-Myc in clear cell renal cell carcinomas is perfectly in
line with the well established function of FBP1 as a tran-
scriptional activator of c-myc. In papillary renal cell carci-
nomas with c-myc gene amplifications [17] one may
expect a disruption of the FUSE/FBP-system. As a conse-
quence, FBP1 expression may trigger increased prolifera-
tion in clear cell, but not in papillary RCC. This would
explain our finding that the Ki-67 labeling index is related
to FBP1 expression only in clear cell RCC, but not in other
tumor subtypes.
Table 2: Associations between FBP1 and -3 and clinical parameters in RCC (low, high expression: for definition see text). 
FPB1 FBP3
n low
n (%)
high
n (%)
p-value n low
n (%)
high
n (%)
p-value
Histology clear cell 83 58
(69.9)
25
(30.1)
0.003# 83 51
(61.4)
32
(38.6)
0.052#
papillary 16 5
(31.3)
11
(68.8)
17 5
(29.4)
12
(70.6)
chromo-phobe 5 5
(100.0)
0
(0)
5 3
(60.0)
2
(40.0)
pT
Stage*
pT1/2 40 30
(75.0)
10
(25.0)
n.s. 40 19
(47.5)
21
(52.5)
0.014
pT3/4 43 28
(65.1)
15
(34.9)
43 32
(74.4)
11
(25.6)
Grade* 1/2 66 48
(72.7)
18
(27.3)
n.s. 66 43
(65.2)
23
(34.8)
n.s.
3/4 17 10
(58.8)
7
(41.2)
17 8
(47.1)
9
(52.9)
FBP1 low 58 58 41
(70.7)
17
(29.3)
0.013
high 25 25 10
(40.0)
15
(60.0)
FBP3 low 51 41
(80.4)
10
(19.6)
0.013 51
high 32 17
(53.1)
15
(46.9)
32
n.s.: not significant
* only clear cell RCC
# Chi square testPage 9 of 11
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FBP3. Although the FBP1 and FBP3 genes are located on
different chromosomes in humans (1p31.1 and 9q34.11,
respectively) they show a strikingly parallel expression
pattern through different tumor entities and tumor sam-
ples within an entity. In a recent study on the three FBPs,
comparing their intrinsic activation and repression, sub-
cellular localization, and in vivo targets, it has been
shown that they usually cooperate to regulate the expres-
sion profiles among a set of common targets [20]. Our
data are consistent with such a high degree of FBP1 and
FBP3 co-regulation and support the notion that even in
neoplastic tissues, where regulatory nexus are expected to
be disturbed, FBPs act synergistically. Urothelial tumors
provide an exception to the tendency of this co-regulation
of the different FBPs. The most frequent genetic alteration
in transitional cell carcinoma of the urinary bladder is par-
ticular loss of chromosome 9 [24]. The partial 9q losses
also involved 9q33–9q34 [25]. Therefore, FBP3 on
9q34.11 may also be a frequent target of 9q losses. This
would explain the disrupted co-expression of FBP1 and
FBP3 in urothelial tumors.
Conclusion
This is the first comprehensive study to investigate expres-
sion patterns of the c-myc regulators FBP in carcinomas of
Table 3: Associations between FBP1 and -3 and tumor grade in non-invasive bladder cancer RCC (low, high expression: for definition 
see text).
FPB1 FBP3
n low
n (%)
high
n (%)
p-value n low
n (%)
high
n (%)
p-value
Grade
(WHO 1973)
G1 27 7
(25.9)
20
(74.1)
n.s.* 24 4
(16.7)
20
(83.3)
n.s.*
G2 80 27
(33.8)
53
(66.3)
74 19
(25.7)
55
(74.3)
G3 5 3
(60.0)
2
(40.0)
4 2
(50.0)
2
(50.0)
Grade (WHO 2004) Low grade 89 25
(28.1)
64
(71.9)
0.029* 81 20
(24.7)
61
(75.3)
n.s.*
High grade 23 12
(52.2)
11
(47.8)
21 5
(23.8)
16
(76.2)
FBP1 low 37 36 12
(33.3)
24
(66.7)
0.067
high 75 64 11
(17.2)
53
(82.8)
FBP3 low 23 12
(52.2)
11
(47.8)
0.067* 25
high 77 24
(31.2)
53
(68.8)
77
n.s.: not significant
* Chi square test for trends
Table 4: Associations between FBP1, FBP-3, c-Myc, and proliferation rate (Ki-67) in clear cell RCC
c-myc Ki-67
n neg.
n (%)
pos.
n (%)
p-value n low
n (%)
high
n (%)
p-value
FBP1 low 58 46
(79.3)
12
(20.7)
0.001 58 49
(84.5)
9
(15.5)
0.001
high 24 9
(37.5)
15
(62.5)
25 5
(20.0)
20
(80.0)
FBP3 low 51 38
(74.5)
13
(25.5)
0.09 51 36
(70.6)
15
(29.4)
n.s.
high 31 17
(54.8)
14
(45.2)
32 18
(56.3)
14
(43.8)
* Chi square test for trendsPage 10 of 11
(page number not for citation purposes)
BMC Cancer 2008, 8:369 http://www.biomedcentral.com/1471-2407/8/369Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
the urinogenital tract. FBP1 and FBP3 were shown to be
co-expressed in most tumor entities. Our data show co-
expression of FBPs and c-myc in vivo, which suggests a
potential role of FBP1 and FBP3 as an activator of c-myc in
clear cell RCC.
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